Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Target Raised at HC Wainwright

Tarsus Pharmaceuticals (NASDAQ:TARS) had its price objective raised by HC Wainwright from $88.00 to $106.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright‘s target price suggests a potential upside of 45.93% from the company’s previous close.

Several other research firms have also issued reports on TARS. Jefferies Financial Group upped their target price on Tarsus Pharmaceuticals from $88.00 to $105.00 and gave the stock a “buy” rating in a report on Tuesday, September 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Thursday, October 15th. Guggenheim lowered their price target on Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating on the stock in a research report on Tuesday, July 21st. The Goldman Sachs Group initiated coverage on Tarsus Pharmaceuticals in a research note on Thursday, September 24th. They set a “buy” rating and a $116.00 price objective on the stock. Finally, Wall Street Zen downgraded shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Tarsus Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $103.43.

Tarsus Pharmaceuticals Price Performance

NASDAQ TARS opened at $72.64 on Wednesday. The firm’s 50 day moving average is $75.17 and its 200-day moving average is $67.87. The company has a quick ratio of 3.17, a current ratio of 3.20 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $3.58 billion, a PE ratio of -66.64 and a beta of 0.34. Tarsus Pharmaceuticals has a 12-month low of $53.89 and a 12-month high of $91.53.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported ($14.40) EPS for the quarter, missing the consensus estimate of ($1.46) by ($12.94). Tarsus Pharmaceuticals had a negative return on equity of 13.53% and a negative net margin of 7.67%. The business had revenue of $194.57 million for the quarter, compared to the consensus estimate of $187.83 million. Equities research analysts anticipate that Tarsus Pharmaceuticals will post -2.23 earnings per share for the current fiscal year.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, insider Elizabeth Lin sold 3,180 shares of the stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $87.50, for a total transaction of $278,250.00. Following the transaction, the insider owned 1,590 shares in the company, valued at $139,125. This represents a 66.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director William Link, PhD sold 12,500 shares of the stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $78.38, for a total value of $979,750.00. Following the sale, the director directly owned 94,487 shares in the company, valued at $7,405,891.06. This represents a 11.68% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 48,031 shares of company stock valued at $4,004,227 in the last quarter. Company insiders own 9.64% of the company’s stock.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of large investors have recently bought and sold shares of the company. Hsbc Holdings PLC raised its position in Tarsus Pharmaceuticals by 295.0% in the second quarter. Hsbc Holdings PLC now owns 38,090 shares of the company’s stock valued at $2,429,000 after purchasing an additional 28,447 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Tarsus Pharmaceuticals during the second quarter worth about $7,204,000. Bank of America Corp DE grew its holdings in shares of Tarsus Pharmaceuticals by 57.5% during the first quarter. Bank of America Corp DE now owns 1,194,377 shares of the company’s stock worth $83,786,000 after purchasing an additional 436,271 shares during the last quarter. TimesSquare Capital Management LLC acquired a new position in shares of Tarsus Pharmaceuticals in the second quarter valued at approximately $23,249,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Tarsus Pharmaceuticals in the second quarter valued at approximately $5,726,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Q3 revenue rose about 64% year over year to $194.6 million, exceeding analyst estimates of $187.8 million. XDEMVY surpassed one million bottles dispensed and $1 billion in cumulative sales since launch. Tarsus Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Management expects XDEMVY sales of $715 million to $730 million in 2026, signaling continued confidence in the drug’s commercial opportunity. Tarsus expects $715M-$730M 2026 XDEMVY sales
• Positive Sentiment: Tarsus’s quarterly loss per share was $0.78, narrower than the $1.43 loss analysts expected, though the loss was larger than a year earlier. Tarsus Pharmaceuticals Reports Q3 Loss, Tops Revenue Estimates
• Negative Sentiment: The company is deferring regulatory filings in Europe and Japan, which could push back its international expansion and potential contribution to sales. Tarsus expects $715M-$730M 2026 XDEMVY sales while deferring Europe and Japan filings

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a commercial-stage ophthalmic pharmaceutical company focused on developing and marketing treatments for eye diseases with significant unmet medical needs. The company’s portfolio is centered on therapies designed to address conditions affecting the ocular surface and eyelids.

Tarsus’ lead product is XDEMVY (lotilaner ophthalmic solution) 0.25%, an eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis, an inflammatory eyelid condition associated with an infestation of Demodex mites.